244 related articles for article (PubMed ID: 32819975)
1. Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity.
Sheybani ND; Witter AR; Thim EA; Yagita H; Bullock TNJ; Price RJ
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819975
[TBL] [Abstract][Full Text] [Related]
2. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR
Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046
[TBL] [Abstract][Full Text] [Related]
3. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization.
Luo B; Song L; Chen L; Cai Y; Zhang M; Wang S
Phytomedicine; 2024 Jul; 129():155675. PubMed ID: 38678954
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional Theranostic Nanoparticles for Enhanced Tumor Targeted Imaging and Synergistic FUS/Chemotherapy on Murine 4T1 Breast Cancer Cell.
Kang Z; Yang M; Feng X; Liao H; Zhang Z; Du Y
Int J Nanomedicine; 2022; 17():2165-2187. PubMed ID: 35592098
[TBL] [Abstract][Full Text] [Related]
5. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
[TBL] [Abstract][Full Text] [Related]
6. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.
Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y
J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938
[TBL] [Abstract][Full Text] [Related]
7. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL
Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209
[TBL] [Abstract][Full Text] [Related]
8. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR
Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420
[TBL] [Abstract][Full Text] [Related]
9. Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
Maletzki C; Wiegele L; Nassar I; Stenzel J; Junghanss C
J Immunother Cancer; 2019 Jan; 7(1):8. PubMed ID: 30630527
[TBL] [Abstract][Full Text] [Related]
10. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
11. Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
Min DJ; He S; Green JE
Anticancer Res; 2016 Jun; 36(6):2649-57. PubMed ID: 27272773
[TBL] [Abstract][Full Text] [Related]
12. Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC.
Stravokefalou V; Stellas D; Karaliota S; Nagy BA; Valentin A; Bergamaschi C; Dimas K; Pavlakis GN
Front Immunol; 2022; 13():1014802. PubMed ID: 36713398
[TBL] [Abstract][Full Text] [Related]
13. Ganoderma lucidum spores-derived particulate β-glucan treatment improves antitumor response by regulating myeloid-derived suppressor cells in triple-negative breast cancer.
Bu Y; Liu Q; Shang Y; Zhao Z; Sun H; Chen F; Ma Q; Song J; Cui L; Sun E; Luo Y; Shu L; Jing H; Tan X
Int J Biol Macromol; 2024 Jun; 270(Pt 1):131949. PubMed ID: 38749890
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
Le HK; Graham L; Cha E; Morales JK; Manjili MH; Bear HD
Int Immunopharmacol; 2009 Jul; 9(7-8):900-9. PubMed ID: 19336265
[TBL] [Abstract][Full Text] [Related]
15. Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
Bazargan S; Bunch B; Ojwang' AME; Blauvelt J; Landin A; Ali J; Abrahams D; Cox C; Hall AM; Beatty MS; Poch M; Rejniak KA; Pilon-Thomas S
Front Immunol; 2023; 14():1275375. PubMed ID: 37901214
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6C
Wu C; Tan X; Hu X; Zhou M; Yan J; Ding C
J Immunol; 2020 Jan; 204(1):212-223. PubMed ID: 31776206
[TBL] [Abstract][Full Text] [Related]
17. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
Fan Y; Wang Q; Lin G; Shi Y; Gu Z; Ding T
Acta Biomater; 2017 Oct; 62():257-272. PubMed ID: 28859899
[TBL] [Abstract][Full Text] [Related]
18. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
Salembier R; De Haes C; Bellemans J; Demeyere K; Van Den Broeck W; Sanders NN; Van Laere S; Lyons TR; Meyer E; Steenbrugge J
Breast Cancer Res; 2024 Apr; 26(1):63. PubMed ID: 38605414
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer.
Singh B; Maharjan S; Pan DC; Zhao Z; Gao Y; Zhang YS; Mitragotri S
Biomaterials; 2022 Jan; 280():121302. PubMed ID: 34894584
[TBL] [Abstract][Full Text] [Related]
20. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]